TY - JOUR
T1 - Monoclonal Antibody Therapy for Hairy Cell Leukemia
AU - Thomas, Deborah A.
AU - Ravandi, Farhad
AU - Kantarjian, Hagop
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/10
Y1 - 2006/10
N2 - The use of MoAb therapy for the treatment of HCL offers great promise and potential for improving progression-free survival. Rituximab has activity in the setting of previously treated HCL and the ability to eradicate MRD after 2-CdA given as frontline therapy. Alemtuzumab, epratuzumab, Hu-Max-CD20, and other candidate MoAb's should be studied in HCL. Appropriate pharmacologic investigations, use of antigen modulation, and assessments of soluble antigen levels should be considered with future clinical trials of MoAb's in HCL to optimize therapeutic strategies.
AB - The use of MoAb therapy for the treatment of HCL offers great promise and potential for improving progression-free survival. Rituximab has activity in the setting of previously treated HCL and the ability to eradicate MRD after 2-CdA given as frontline therapy. Alemtuzumab, epratuzumab, Hu-Max-CD20, and other candidate MoAb's should be studied in HCL. Appropriate pharmacologic investigations, use of antigen modulation, and assessments of soluble antigen levels should be considered with future clinical trials of MoAb's in HCL to optimize therapeutic strategies.
UR - http://www.scopus.com/inward/record.url?scp=33748752626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748752626&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2006.06.011
DO - 10.1016/j.hoc.2006.06.011
M3 - Review article
C2 - 16990112
AN - SCOPUS:33748752626
SN - 0889-8588
VL - 20
SP - 1125
EP - 1136
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 5
ER -